3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Neuroblastoma
2
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Hodgkin Disease
1
Hepatoblastoma
1
Ganglioneuroblastoma
1
Interventions
Cisplatin
6
Platinum
5
Pemetrexed
5
1,2-diaminocyclohexaneplatinum II citrate
5
pembrolizumab
4
atezolizumab
2
Radiotherapy
2
Radiation
2
Nivolumab
2
Ipilimumab
2
Gemcitabine
2
Cyclophosphamide
2
Carboplatin
2
tremelimumab
1
methoxyamine
1
fludarabine
1
decitabine and cedazuridine drug combination
1
cediranib
1
anetumab ravtansine
1
aldesleukin
1
Trioxsalen
1
Tissue Banks
1
Radiotherapy, Intensity-Modulated
1
Proton Therapy
1
Phototherapy
1
Photochemotherapy
1
Pharmacogenomic Testing
1
Pharmaceutical Preparations
1
Interleukin-2
1
Influenza Vaccines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
Influenza Vaccines
×
90 days
×
Clear all
NCT07510815
2026-04-06
DUAL-MESO-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled